Interesting RXRX Put And Call Options For March 27th

Recursion Pharmaceuticals (RXRX) is trading at $3.77 while Stock Options Channel highlights two option strategies: a sell-to-open $3.00 put bid at $0.09 (net cost basis $2.91) which is ~20% OTM with a 76% probability of expiring worthless and a 3.00% cash-commitment return (22.37% annualized). The $4.00 call is bid $0.30 and, if used as a covered call against shares bought at $3.77, would produce a 14.06% total return to expiration (March 27) and a 7.96% premium boost if it expires worthless (59.33% annualized); implied volatilities are 316% (put) and 121% (call) versus trailing 12-month volatility of 88%.

Analysis

Market structure: Option buyers of downside protection (put holders) and speculators seeking asymmetric upside are the immediate winners; market makers and liquidity providers capture skew premium (put IV 316% vs call IV 121%). Retail or value investors able to accept equity ownership benefit if they can acquire RXRX below current $3.77 — e.g., via selling the Mar-27 $3 put and lowering cost basis to $2.91. The broader biotech tape is unaffected structurally, but heavy put demand/IV skew signals concentrated downside concerns and potential for episodic volatility that can bleed into small-cap biotech ETFs.

Risk assessment: Tail risks include clinical failure, urgent dilutive financing, or major administration/regulatory actions that could drop shares >50% (plausible given IV and float concentration). Immediate horizon: option expirations on Mar-27 create a squeeze window (days); short-term (weeks–months) hinges on fundraising and press releases; long-term (quarters–years) depends on pipeline milestones and cash runway. Hidden dependencies: borrow/short-interest and upcoming financing cadence — a modest raise would dilute and reset option pricing; high put IV suggests asymmetric downside probability not captured by spot price.

Trade implications: Tactical income trade — sell-to-open Mar-27 $3 puts (collect $0.09) sized small (0.5–1.5% portfolio, max assignment target price $2.91) or convert to a put-credit spread (sell $3 / buy $2) to cap tail risk. Covered-call play — buy RXRX at $3.77 and sell Mar-27 $4 call (collect $0.30) for a capped 14.06% return to $4; limit exposure to 1–2% portfolio given binary risk. Volatility arb: avoid long straddles (IV rich); consider calendar spreads to sell short-dated high-IV puts and buy longer-dated protection if conviction in long-term thesis.

Contrarian angles: Consensus may be overstating permanent impairment risk (puts imply >300% IV) while underestimating near-term positive idiosyncratic moves — a successful readout could push shares >100% quickly, making covered calls costly. Conversely, the market may be underpricing dilution risk: if cash runway <6 months, issuance could compress equity >30%. Unintended consequence: selling puts into thin post-assignment markets risks forced accumulation on adverse tape; set strict size and stop-loss thresholds (e.g., cut equity if share < $2.50).

Key Decisions for Investors

• Establish a tactical, size-constrained position: sell-to-open Mar-27 RXRX $3 puts (collect $0.09) sized to represent 0.5–1.5% portfolio exposure with explicit readiness to be assigned at $2.91; if assigned, set stop-loss at $2.50 (loss ~14%).
• If willing to own equity, buy RXRX at market ($3.77) and sell Mar-27 $4 calls (covered call) to collect $0.30; cap position to 1–2% portfolio and roll or close before any clinical/financing announcement to avoid being called away or squeezed.
• Prefer defined-risk spreads: if selling puts, use put-credit spread (sell $3 / buy $2) to cap downside; target net credit ≥ $0.04 and max loss $0.96 per spread — use for 0.5% portfolio exposure to limit tail risk.
• Avoid long volatility plays (straddles) given elevated IV; instead, if bullish multi-quarter, buy longer-dated calls (LEAPS) post any dilution event and after IV normalizes below 150% to gain asymmetric upside with limited theta decay.
• Monitor three binary catalysts in next 30–90 days before adding size: announced cash runway <6 months, any clinical readout/partnership, and a financing term sheet; increase allocation only if runway extends >12 months or a clear positive catalyst materializes.